– Phase 1 clinical trial to be initiated in Q1 2023 – The first clinical stage gene therapy for treatment of nAMD that targets all known subtypes of VEGF and ANG2
PHILADELPHIA–(BUSINESS WIRE) — Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031, a recombinant adeno-associated virus (rAAV) based gene therapy that is being studied for the treatment of neovascular Age Related Macular Degeneration (nAMD), the leading cause of severe vision loss and irreversible blindness worldwide. Read full press release